Abstract
Transdermal hormone replacement therapy (HRT) is now an accepted form of treatment, but the long-term skeletal effects have not been assessed. Sixty-six early postmenopausal women were randomized to receive either transdermal HRT (continuous 17β-oestradiol 0.05 mg/day, with 0.25 mg/day of norethisterone acetate added for 14 days of each 28-day cycle) or oral HRT (continuous conjugated equine oestrogens 0.625 mg/day, with 0.15 mg/day dl-norgestrel added for 12 days of each 28-day cycle). Treatment was given for 3 years and 30 matched untreated women were studied concurrently as a control group. Bone density was measured in the lumbar spine and proximal femur by dual-photon absorptiometry at 6-monthly intervals. Bone turnover was assessed by measurement of biochemical markers. At 3 years bone density had declined by 4% in the lumbar spine and by more than 5% in the femoral neck in the untreated group. By comparison bone density increased in both treatment groups at both sites (p<0.001 vs. untreated) and biochemical measurements indicated a significant reduction in bone turnover. There were no significant differences between the treatment groups. Twelve per cent of women on transdermal or oral treatments lost a significant amount of bone from the femoral neck by 3 years despite adequate compliance. Women taking therapy primarily for hip fracture prevention may require a follow-up bone density measurement to establish the efficacy of treatment.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Lindsay R, Hart DM, Aitken JM, MacDonald EB, Anderson JB, Clarke AC. Long-term prevention of postmenopausal osteoporosis by oestrogen. Lancet 1976;1:1038–41.
Christiansen C, Christensen MS, McNair P, Hagen C, Stocklund K, Transbol IB. Prevention of early postmenopausal bone loss: controlled 2-year study in 315 normal females. Eur J Clin Invest 1980;10:273–9.
Genant HK, Cann CE, Ettinger B, Gordan GS, Quantitative computed tomography of vertebral spongiosa: a sensitive method for detecting early bone loss after oopherectomy. Arch Intern Med 1982;97:699–705.
Riis BJ, Thomsen K, Strom V, Christiansen C. The effect of percutaneous estradiol and natural progesterone on postmenopausal bone loss. Am J Obstet Gynecol 1987;156:61–5.
Stevenson JC, Cust MP, Gangar KF, Hillard TC, Lees B, Whitehead MI. Effects of transdermal versus oral hormone replacement therapy on bone density in spine and proximal femur in postmenopausal women. Lancet 1990;335:265–9.
Lindsay R, Tohme JF. Estrogen treatment of patients with established postmenopausal osteoporosis. Obstet Gynecol 1990;76:290–5.
Hutchinson TA, Polansky SM, Feinstein A. Postmenopausal oestrogens protect against fractures of hip and distal radius. Lancet 1979;2:706–9.
Kiel DP, Felson DT, Anderson JJ, Wilson PWF, Moskowitz MA. Hip fracture and the use of estrogens in postmenopausal women. N Engl J Med 1987;317:1169–74.
Stevenson JC, Whitehead MI. Postmenopausal osteoporosis. BMJ 1982;285:585–8.
Whitehead MI, Fraser D, Schenkel L, Crook D, Stevenson JC. Transdermal administration of oestrogen/progestagen hormone replacement therapy. Lancet 1990;335:310–2.
Crook D, Cust MP, Gangar KF, et al. Comparison of transdermal and oral estrogen/progestogen replacement therapy: effects on serum lipids and lipoproteins. Am J Obstet Gynecol 1992;166:950–5.
Sallis JF, Haskell WL, Wood PD, et al. Physical activity assessment methodology in the five city project. Am J Epidemiol 1985;121:91–106.
Lees B, Stevenson JC. An evaluation of dual-energy X-ray absorptiometry and comparison with dual-photon absorptiometry. Osteoporosis Int 1992;2:146–52.
Cooper C, Barker DJP, Morris J, Briggs RSJ. Osteoporosis, falls and age in fracture of the proximal femur. BMJ 1987;295:13–5.
Hillard TC, Bourne TH, Whitehead MI, Crayford TB, Collins WP, Campbell S. Differential effects of transdermal estradiol and sequential progestogens on impedance to flow within the uterine arteries of postmenopausal women. Fertil Steril 1992;58:959–63.
Gangar KF, Vyas S, Whitehead MI, Crook D, Miere H, Campbell S. Pulsatililty index in the internal carotid artery is influenced by transdermal oestradiol and time since menopause. Lancet 1991;338:839–42.
Lindsay R, Hart DM. The minimum effective dose of oestrogen for the prevention of postmenopausal bone loss. Obstet Gynecol 1984;63:759–73.
Christiansen C, Christensen MS, Larsen NE, Transbol IB. Pathophysiological mechanisms of oestrogen effect on bone metabolism. Dose-response relationships in early postmenopausal women. J Clin Endocrinol Metab 1982;55:1124–30.
Ettinger B, Genant HK, Steiger D, Madwig P. Low-dosage micronised 17-β oestradiol prevents bone loss in postmenopausal women. Am J Obstet Gynecol 1992;166:479–88.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Hillard, T.C., Whitcroft, S.J., Marsh, M.S. et al. Long-term effects of transdermal and oral hormone replacement therapy on postmenopausal bone loss. Osteoporosis Int 4, 341–348 (1994). https://doi.org/10.1007/BF01622195
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01622195